| |
The 6th Edition is in stock!
Pay on-line for
a single book with Quick Pay, or see How To Order for more info.
News on the UroAnki Deck
Adobe Genp 2023 [repack] -
Adobe offers a massive discount (up to 60% off) on the All Apps plan for students and educators.
Adobe GenP 2023 is a third-party patching tool designed for the Windows operating system. Its primary purpose is to bypass the licensing and activation mechanisms of Adobe Creative Cloud 2023 applications.
As 2023 closed, Adobe made two strategic moves: adobe genp 2023
: Advanced users often manually block Adobe’s inbound and outbound connections via a firewall to prevent the software from "calling home" and triggering trial expiration warnings. Safety and Security Risks
Users usually install the official Creative Cloud desktop app, download the "trial" versions of the software they want, and then run GenP to "cure" those trials into full, unrestricted versions. Critical Risks and Considerations Adobe offers a massive discount (up to 60%
"Clean" versions exist, but mirrors on random websites or Discord channels often bundle GenP with actual trojans or data stealers.
To help me provide more relevant information, tell me if you are looking for for a specific task, need help finding official Adobe discounts , or want to know more about Creative Cloud system requirements . Share public link As 2023 closed, Adobe made two strategic moves:
Using activation patches like GenP constitutes a violation of Adobe’s End User License Agreement (EULA) and falls under digital piracy laws in most jurisdictions.
Unlike older piracy methods that relied on modified installers (repacks) which could easily bundle malware, GenP operates on a "clean download" philosophy.
Because GenP is an unofficial tool distributed through third-party forums, file-sharing sites, and Reddit communities, it is a prime target for cybercriminals. Malicious actors frequently bundle genuine versions of GenP with Trojans, ransomware, cryptominers, or info-stealers. Furthermore, because the tool modifies system-level .dll files, Windows Defender and third-party antivirus programs will almost always flag it as a "False Positive" or a generic threat, making it incredibly difficult for an average user to distinguish between a clean patcher and actual malware. 2. Legal and Ethical Concerns
On the other hand, . With the introduction of Adobe Firefly and Sensei GenAI , Adobe has not only justified its subscription model but has also delivered transformative value to its paying customers. These generative AI tools accelerate creativity, automate tedious tasks, and unlock entirely new forms of artistic expression that are safe, legal, and continuously improving .
Info on 6 edition: The 6th edition is available in print form. The
6th edition is 150 pages longer then the previous edition. It now has
754 pages of urology content. The book became too thick to be managed
effectively as a single volume using a spiral binding. So, the book has been separated into 2 volumes: oncology and non-oncology (each volume is spiral bound). When you purchase the book, you receive volumes 1 & 2 (the volumes are not sold separately).
There
are no new chapters, but here have been updates/additions to almost
every chapter. For a brief list of the updates, see below.
The
Pocket
Guide to Urology - 6th Edition
Since
the first edition
was released in
1999, the Pocket Guide to Urology has become one of the most popular
urology texts. Nearly 50,000 copies of the Pocket Guide to Urology have
been
printed and
distributed worldwide (over 50 countries on 6 continents). The 6th
edition is currently for sale.
The 6th edition of the Pocket
Guide
to Urology is a comprehensive evidence-based reference book that
emphasizes
clinical guidelines, consensus statements, and landmark
studies. Information
is compiled and is
presented in a thorough, organized, and logical format.
Each chapter contains detailed references.
The 6th edition of the Pocket
Guide to Urology contains a plethora of new information (see what is new).
It has 754
pages and contains the following
chapters:


|
|
|
Contents
Renal
Tumors
Wilms’ Tumor
& Other Pediatric Renal Tumors
Bladder Tumors
Upper Tract Urothelial Tumors
Tumor Markers for Urothelial Cancer
Penile
Tumors
Testicular Tumors
Prostate Cancer
Androgen
Deprivation
Prostate
Specific Antigen (PSA)
Voiding
& Urodynamics
Benign
Prostatic
Hyperplasia
Urinary
Incontinence: General Concepts
Urge Incontinence &
Overactive Bladder
Stress Incontinence in the Female
Stress
Incontinence in the Male
Hematuria
Urolithiasis
Strictures of the Lower Urinary Tract
Strictures
of the Upper Urinary
Tract
Imaging
& Radiology
Embryology
Pregnancy:
Urologic
Considerations
Vesicoureteral
Reflux (VUR)
Erectile
Dysfunction (ED)
Male Hypogonadism
Ejaculatory
Disorders
Male
Infertility
Emergent
Urologic Conditions
Priapism
Genitourinary
Trauma
Genitourinary
Infections: General Concepts
Lower Urinary Tract Infections
Upper
Urinary Tract Infections
Genital Infections
Prostatitis
& Prostate Infections
Sexually
Transmitted Diseases
Gas
Forming Infections
Fungal Infections
Malacoplakia
&
Tuberculosis
Surgical
Principles for the
Urologist
Ureteral Stents
Use of Intestine in the
Urinary
Tract
Doses of Commonly
Used
Medications
Formulas and Conversions |
|
|
|
Updates in the 6th Edition
Updates/additions to the 6th edition include:
● NCCN - 2021 guidelines
● AUA - most recent guidelines
● EAU - 2021 guidelines
● Many other recent guidelines including CDC, WHO, Infectious Diseases Society of America (ISDA),
American Association for the Surgery of Trauma (AAST), American College
of Radiology (ACR),
European Society of Urogenital Radiology, American College of
Obstetricans and Gynecologists,
International Continence Society (ICS), etc.
● Updates and addition of landmark studies.
● New medications: Jatenzo, Vibegron, Lumasiran, Relugolix, jelmyto,
PARP inhibitors (Olaparib, Rucaparib),
PDL/PDL1 inhibitors (Pembrolizumab, Erdafitinib), etc.
● Updates of all flowsheets and diagrams to reflect the most recent
guidelines and data.
● Update on Bozniak classifiation
● PET/CT information including flucyclovine and PSMA.
● Expanded section on MRI, including MRI guided prostate biopsy, MRI for cancer surveillance, etc.
● Expanded on genetic risks for the various cancers, somatic & germline tests, and testing guidelines.
● More info on molecular testing for prostate cancer: decipher, oncotype dx, prolaris, etc.
● Newest studies on salvage and adjuvant XRT after RP for prostate cancer
● Newer BPH treatments (acquablation, resume, etc).
● Updates and additions to almost every chapter.
Pocket
Guide to
Urology, Sixth Edition - Copyright 2021 by Jeff A. Wieder.
All rights reserved.
This website was last updated May 2, 2026.
|
|